FNY Managed Accounts’s Sage Therapeutics SAGE Stock Holding History

FNY Managed Accounts’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-105	Closed	-$7K	–	530
2017 Q1	$7K	Buy	+105	New	+$6.15K	0.02%	564

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FNY Managed Accounts's SAGE Position: Q2 2017 in Review

FNY Managed Accounts sold out of Sage Therapeutics (SAGE) in Q2 2017, closing a stake of 105 shares — an estimated $7K sold.

FNY Managed Accounts first reported a position in SAGE in Q1 2017 and held it in 1 quarter. The position peaked at $7K in Q1 2017. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

FNY Managed Accounts reported no remaining Sage Therapeutics position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 105 Sage Therapeutics shares in Q2 2017, an estimated $7K.
FNY Managed Accounts first reported a position in Sage Therapeutics in Q1 2017 and held it in 1 quarter.
FNY Managed Accounts's Sage Therapeutics position peaked at $7K in Q1 2017.
191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.